Abstract
Summary
Osteoporosis is a disease where decreased bone strength increases the risk of a broken bone. It is the most common reason for a broken bone among the elderly. Bones that commonly break include the back bones, the bones of the forearm, and the hip. Until a broken bone occurs there are typically no symptoms. Bones may weaken to such a degree that a break may occur with minor stress or spontaneously. Chronic pain and a decreased ability to carry out normal activities may occur following a broken bone.
Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.
The global Osteoporosis Drugs market is projected to reach US$ million by 2030 from an estimated US$ million in 2024, at a CAGR of % during 2024 and 2030.
In Brazil, Osteoporosis Drugs key players include Eli Lilly, Novartis, Pfizer, etc. Global top three manufacturers hold a share over 35%.
In terms of product, Antiresorptive Drugs is the largest segment, with a share over 70%. And in terms of application, the largest application is Female, followed by Male.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Osteoporosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Osteoporosis Drugs.
The Osteoporosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Osteoporosis Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Osteoporosis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application, and regions.
Market Segmentation
By Company
Eli Lilly
Novartis
Pfizer
Amgen
Merck
Novo nordisk
Actavis
Roche
Segment by Type
Antiresorptive Drugs
Anabolic Drugs
Segment by Application
Female
Male
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Osteoporosis Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Osteoporosis Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Osteoporosis Drugs sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
Osteoporosis may be due to lower than normal peak bone mass and greater than normal bone loss. Bone loss increases after menopause due to lower levels of estrogen. Osteoporosis may also occur due to a number of diseases or treatments including alcoholism, anorexia, hyperthyroidism, surgical removal of the ovaries, and kidney disease. Certain medications increase the rate of bone loss including some antiseizure medications, chemotherapy, proton pump inhibitors, selective serotonin reuptake inhibitors, and steroids. Not enough exercise and smoking are also risk factors. Osteoporosis is defined as a bone density of 2.5 standard deviations below that of a young adult. This is typically measured by dual-energy X-ray absorptiometry at the hip.
The global Osteoporosis Drugs market is projected to reach US$ million by 2030 from an estimated US$ million in 2024, at a CAGR of % during 2024 and 2030.
In Brazil, Osteoporosis Drugs key players include Eli Lilly, Novartis, Pfizer, etc. Global top three manufacturers hold a share over 35%.
In terms of product, Antiresorptive Drugs is the largest segment, with a share over 70%. And in terms of application, the largest application is Female, followed by Male.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Osteoporosis Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Osteoporosis Drugs.
The Osteoporosis Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Osteoporosis Drugs market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Osteoporosis Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application, and regions.
Market Segmentation
By Company
Eli Lilly
Novartis
Pfizer
Amgen
Merck
Novo nordisk
Actavis
Roche
Segment by Type
Antiresorptive Drugs
Anabolic Drugs
Segment by Application
Female
Male
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Osteoporosis Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Osteoporosis Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Osteoporosis Drugs sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
Table of Contents
1 Study Coverage
1.1 Osteoporosis Drugs Product Introduction
1.2 Market by Type
1.2.1 Global Osteoporosis Drugs Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 Antiresorptive Drugs
1.2.3 Anabolic Drugs
1.3 Market by Application
1.3.1 Global Osteoporosis Drugs Market Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Female
1.3.3 Male
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Osteoporosis Drugs Market Size Estimates and Forecasts
2.1.1 Global Osteoporosis Drugs Revenue 2019-2030
2.1.2 Global Osteoporosis Drugs Sales 2019-2030
2.2 Osteoporosis Drugs Market Size by Region: 2023 Versus 2030
2.3 Osteoporosis Drugs Sales by Region (2019-2030)
2.3.1 Global Osteoporosis Drugs Sales by Region: 2019-2024
2.3.2 Global Osteoporosis Drugs Sales Forecast by Region (2025-2030)
2.3.3 Global Osteoporosis Drugs Sales Market Share by Region (2019-2030)
2.4 Osteoporosis Drugs Market Estimates and Projections by Region (2025-2030)
2.4.1 Global Osteoporosis Drugs Revenue by Region: 2019-2024
2.4.2 Global Osteoporosis Drugs Revenue Forecast by Region (2025-2030)
2.4.3 Global Osteoporosis Drugs Revenue Market Share by Region (2019-2030)
3 Global Osteoporosis Drugs by Manufacturers
3.1 Global Top Osteoporosis Drugs Manufacturers by Sales
3.1.1 Global Osteoporosis Drugs Sales by Manufacturer (2019-2024)
3.1.2 Global Osteoporosis Drugs Sales Market Share by Manufacturer (2019-2024)
3.2 Global Top Osteoporosis Drugs Manufacturers by Revenue
3.2.1 Global Osteoporosis Drugs Revenue by Manufacturer (2019-2024)
3.2.2 Global Osteoporosis Drugs Revenue Share by Manufacturer (2019-2024)
3.3 Global Osteoporosis Drugs Price by Manufacturer (2019-2024)
3.4 Competitive Landscape
3.4.1 Key Osteoporosis Drugs Manufacturers Covered: Ranking by Revenue
3.4.2 Global Osteoporosis Drugs Market Concentration Ratio (CR5 and HHI) & (2019-2024)
3.4.3 Global Osteoporosis Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.5 Global Osteoporosis Drugs Manufacturing Base Distribution, Product Type
3.5.1 Osteoporosis Drugs Manufacturers Manufacturing Base Distribution, Headquarters
3.5.2 Manufacturers Osteoporosis Drugs Product Type
3.5.3 Date of International Manufacturers Enter into Osteoporosis Drugs Market
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Eli Lilly
4.1.1 Eli Lilly Company Information
4.1.2 Eli Lilly Description, Business Overview
4.1.3 Eli Lilly Osteoporosis Drugs Products Offered
4.1.4 Eli Lilly Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
4.1.5 Eli Lilly Osteoporosis Drugs Sales by Product in 2023
4.1.6 Eli Lilly Osteoporosis Drugs Sales by Application in 2023
4.1.7 Eli Lilly Osteoporosis Drugs Sales by Geographic Area in 2023
4.1.8 Eli Lilly Recent Developments
4.2 Novartis
4.2.1 Novartis Company Information
4.2.2 Novartis Description, Business Overview
4.2.3 Novartis Osteoporosis Drugs Products Offered
4.2.4 Novartis Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
4.2.5 Novartis Osteoporosis Drugs Sales by Product in 2023
4.2.6 Novartis Osteoporosis Drugs Sales by Application in 2023
4.2.7 Novartis Osteoporosis Drugs Sales by Geographic Area in 2023
4.2.8 Novartis Recent Developments
4.3 Pfizer
4.3.1 Pfizer Company Information
4.3.2 Pfizer Description, Business Overview
4.3.3 Pfizer Osteoporosis Drugs Products Offered
4.3.4 Pfizer Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
4.3.5 Pfizer Osteoporosis Drugs Sales by Product in 2023
4.3.6 Pfizer Osteoporosis Drugs Sales by Application in 2023
4.3.7 Pfizer Osteoporosis Drugs Sales by Geographic Area in 2023
4.3.8 Pfizer Recent Developments
4.4 Amgen
4.4.1 Amgen Company Information
4.4.2 Amgen Description, Business Overview
4.4.3 Amgen Osteoporosis Drugs Products Offered
4.4.4 Amgen Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
4.4.5 Amgen Osteoporosis Drugs Sales by Product in 2023
4.4.6 Amgen Osteoporosis Drugs Sales by Application in 2023
4.4.7 Amgen Osteoporosis Drugs Sales by Geographic Area in 2023
4.4.8 Amgen Recent Developments
4.5 Merck
4.5.1 Merck Company Information
4.5.2 Merck Description, Business Overview
4.5.3 Merck Osteoporosis Drugs Products Offered
4.5.4 Merck Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
4.5.5 Merck Osteoporosis Drugs Sales by Product in 2023
4.5.6 Merck Osteoporosis Drugs Sales by Application in 2023
4.5.7 Merck Osteoporosis Drugs Sales by Geographic Area in 2023
4.5.8 Merck Recent Developments
4.6 Novo nordisk
4.6.1 Novo nordisk Company Information
4.6.2 Novo nordisk Description, Business Overview
4.6.3 Novo nordisk Osteoporosis Drugs Products Offered
4.6.4 Novo nordisk Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
4.6.5 Novo nordisk Osteoporosis Drugs Sales by Product in 2023
4.6.6 Novo nordisk Osteoporosis Drugs Sales by Application in 2023
4.6.7 Novo nordisk Osteoporosis Drugs Sales by Geographic Area in 2023
4.6.8 Novo nordisk Recent Development
4.7 Actavis
4.7.1 Actavis Company Information
4.7.2 Actavis Description, Business Overview
4.7.3 Actavis Osteoporosis Drugs Products Offered
4.7.4 Actavis Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
4.7.5 Actavis Osteoporosis Drugs Sales by Product in 2023
4.7.6 Actavis Osteoporosis Drugs Sales by Application in 2023
4.7.7 Actavis Osteoporosis Drugs Sales by Geographic Area in 2023
4.7.8 Actavis Recent Development
4.8 Roche
4.8.1 Roche Company Information
4.8.2 Roche Description, Business Overview
4.8.3 Roche Osteoporosis Drugs Products Offered
4.8.4 Roche Osteoporosis Drugs Sales, Revenue and Gross Margin (2019-2024)
4.8.5 Roche Osteoporosis Drugs Sales by Product in 2023
4.8.6 Roche Osteoporosis Drugs Sales by Application in 2023
4.8.7 Roche Osteoporosis Drugs Sales by Geographic Area in 2023
4.8.8 Roche Recent Development
5 Breakdown Data by Type
5.1 Global Osteoporosis Drugs Sales by Type (2019-2030)
5.1.1 Global Osteoporosis Drugs Sales by Type (2019-2024)
5.1.2 Global Osteoporosis Drugs Sales Forecast by Type (2025-2030)
5.1.3 Global Osteoporosis Drugs Sales Market Share by Type (2019-2030)
5.2 Global Osteoporosis Drugs Revenue Forecast by Type (2019-2030)
5.2.1 Global Osteoporosis Drugs Revenue by Type (2019-2024)
5.2.2 Global Osteoporosis Drugs Revenue Forecast by Type (2025-2030)
5.2.3 Global Osteoporosis Drugs Revenue Market Share by Type (2019-2030)
5.3 Osteoporosis Drugs Average Selling Price (ASP) by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Osteoporosis Drugs Sales by Application (2019-2030)
6.1.1 Global Osteoporosis Drugs Sales by Application (2019-2024)
6.1.2 Global Osteoporosis Drugs Sales Forecast by Application (2025-2030)
6.1.3 Global Osteoporosis Drugs Sales Market Share by Application (2019-2030)
6.2 Global Osteoporosis Drugs Revenue Forecast by Application (2019-2030)
6.2.1 Global Osteoporosis Drugs Revenue by Application (2019-2024)
6.2.2 Global Osteoporosis Drugs Revenue Forecast by Application (2025-2030)
6.2.3 Global Osteoporosis Drugs Revenue Market Share by Application (2019-2030)
6.3 Osteoporosis Drugs Average Selling Price (ASP) by Application (2019-2030)
7 North America
7.1 North America Osteoporosis Drugs Market Size YoY Growth 2019-2030
7.2 North America Osteoporosis Drugs Market Facts & Figures by Country
7.2.1 North America Osteoporosis Drugs Sales by Country (2019-2030)
7.2.2 North America Osteoporosis Drugs Revenue by Country (2019-2030)
7.3 North America Osteoporosis Drugs Sales by Type (2019-2024)
7.4 North America Osteoporosis Drugs Sales by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Osteoporosis Drugs Market Size YoY Growth 2019-2030
8.2 Asia-Pacific Osteoporosis Drugs Market Facts & Figures by Region
8.2.1 Asia-Pacific Osteoporosis Drugs Sales by Region (2019-2030)
8.2.2 Asia-Pacific Osteoporosis Drugs Revenue by Region (2019-2030)
8.3 Asia-Pacific Osteoporosis Drugs Sales by Type (2019-2024)
8.4 Asia-Pacific Osteoporosis Drugs Sales by Application (2019-2024)
9 Europe
9.1 Europe Osteoporosis Drugs Market Size YoY Growth 2019-2030
9.2 Europe Osteoporosis Drugs Market Facts & Figures by Country
9.2.1 Europe Osteoporosis Drugs Sales by Country (2019-2030)
9.2.2 Europe Osteoporosis Drugs Revenue by Country (2019-2030)
9.3 Europe Osteoporosis Drugs Sales by Type (2019-2024)
9.4 Europe Osteoporosis Drugs Sales by Application (2019-2024)
10 Latin America
10.1 Latin America Osteoporosis Drugs Market Size YoY Growth 2019-2030
10.2 Latin America Osteoporosis Drugs Market Facts & Figures by Country
10.2.1 Latin America Osteoporosis Drugs Sales by Country (2019-2030)
10.2.2 Latin America Osteoporosis Drugs Revenue by Country (2019-2030)
10.3 Latin America Osteoporosis Drugs Sales by Type (2019-2024)
10.4 Latin America Osteoporosis Drugs Sales by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Osteoporosis Drugs Market Size YoY Growth 2019-2030
11.2 Middle East and Africa Osteoporosis Drugs Market Facts & Figures by Country
11.2.1 Middle East and Africa Osteoporosis Drugs Sales by Country (2019-2030)
11.2.2 Middle East and Africa Osteoporosis Drugs Revenue by Country (2019-2030)
11.3 Middle East and Africa Osteoporosis Drugs Sales by Type (2019-2024)
11.4 Middle East and Africa Osteoporosis Drugs Sales by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Osteoporosis Drugs Supply Chain Analysis
12.2 Osteoporosis Drugs Key Raw Materials and Upstream Suppliers
12.3 Osteoporosis Drugs Clients Analysis
12.4 Osteoporosis Drugs Sales Channel and Sales Model Analysis
12.4.1 Osteoporosis Drugs Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Osteoporosis Drugs Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Osteoporosis Drugs Distributors
13 Market Dynamics
13.1 Osteoporosis Drugs Industry Trends
13.2 Osteoporosis Drugs Market Drivers
13.3 Osteoporosis Drugs Market Challenges
13.4 Osteoporosis Drugs Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer